Stock Monitor: Rockwell Medical Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Pfizer Inc. (NYSE: PFE). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=PFE as the Company's latest news hit the wire. On March 19, 2018, BioDuro LLC, which is a global life science research and development (R&D) organization, announced that it has created AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline reagent for the synthesis of fluorosulfates and sulfamoyl fluorides, in a research collaboration with Pfizer, America's leading biopharmaceutical Company. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Rockwell Medical, Inc. (NASDAQ: RMTI), which also belongs to the Healthcare sector as the Company Pfizer. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=RMTI
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Pfizer most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=PFE
BioDuro is Addressing Need to Convert Toxic and Unstable Fluorosulfonate Gas into Stable Solid Form
The currently utilized method of synthesis relies on the use of sulfuryl fluoride gas, which is a colorless, odorless, and toxic gas that requires specialized equipment and additional safety precautions when using. BioDuro is addressing the need to convert this toxic and unstable fluorosulfonate gas into a stable solid form. It is leading the way to extensive adoption of fluorosulfates as reagents in applications ranging from chemical biology to polymer chemistry.
Three important attributes were sought for a solid reagent that could be an alternative to sulfuryl fluoride gas:
- The reagent must demonstrate comparable or improved reactivity to sulfuryl fluoride gas.
- It must be a crystalline, shelf-stable and easily manipulated solid.
- It must be readily accessible for manufacturing on a large scale from commercially available starting materials.
Creation of AISF is a Result of Collaboration between Pfizer's and BioDuro's Chemistry Teams
Commenting on the agreement, Cyrus K. Mirsaidi, President and Chief Executive Officer (CEO) of BioDuro, stated that this breakthrough is just one example of what deeply committed and engaged scientists can achieve in a collaborative environment. Mirsaidi added that the creation of AISF and its development into a commercially viable and environmentally safe product, is a result of a collaboration between Pfizer's and BioDuro's chemistry teams, one that BioDuro looks forward to continuing as it seeks to address new challenges.
About AISF
AISF is a stable, crystalline solid that allows for a user-friendly fluorosulfonation reaction set-up, and it has excellent substrate scope. The reagent is easily manipulated in an open atmosphere and is stable at ambient temperature as either a solid or in solution, over a prolonged period of time. The utility of AISF is demonstrated in the synthesis of a diverse array of aryl fluorosulfates and sulfamoyl fluorides under mild conditions. Additionally, a single-step preparation of AISF was developed that installed the bis(fluorosulfonyl)imide group on acetanilide utilizing an oxidative C-H functionalization protocol.
About BioDuro LLC
Based in San Diego, California, BioDuro is a life sciences research organization, providing drug discovery services for life science, biotechnology, and pharmaceutical industries worldwide. The Company offers services in the areas of chemistry, discovery biology, drug metabolism and pharmacokinetics, and pharmacology, as well as integrated pre-clinical research and development.
About Pfizer Inc.
Founded in 1848 and headquartered in New York City, New York, Pfizer is a leading research-based biopharmaceutical organization. The Company applies science and its global resources to deliver innovative therapies that extend and significantly improve lives. Pfizer also collaborates with healthcare providers, governments, and local communities to support and expand access to reliable, affordable healthcare around the world.
Stock Performance Snapshot
March 20, 2018 - At Tuesday's closing bell, Pfizer's stock ended the trading session flat at $36.33.
Volume traded for the day: 19.10 million shares.
Stock performance in the last month - up 0.19%; previous six-month period - up 2.19%; past twelve-month period - up 5.67%; and year-to-date - up 0.30%
After yesterday's close, Pfizer's market cap was at $216.67 billion.
Price to Earnings (P/E) ratio was at 20.76.
The stock has a dividend yield of 3.74%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
